Long-term efficacy of infliximab for refractory ulcerative colitis: Results from a single center experience

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Yamada, Satoshi ^a   Yoshino, Takuya ^a   Matsuura, Minoru ^a   Minami, Naoki ^a   Toyonaga, Takahiko ^b   Honzawa, Yusuke ^a   Tsuji, Yoshihisa ^a   Nakase, Hiroshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Immunomodulator; Infliximab; Infliximab intensification; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; MESALAZINE; TACROLIMUS; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ANAPHYLACTIC SHOCK; ARTICLE; CLINICAL ARTICLE; COLON RESECTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFUSION RELATED REACTION; JAPAN; MALE; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; COHORT ANALYSIS; COLITIS, ULCERATIVE; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; COHORT STUDIES; COLITIS, ULCERATIVE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899928736     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-80     Document Type: Article

References (30)

1. Rostholder E, Ahmed A, Cheifetz AS, Moss AC. Outcomes after escalation of infliximabtherapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther 2012, 35:562-567. 10.1111/j.1365-2036.2011.04986.x, 3277945, 22239070.
2. Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Poleski M, Dallaire C, Rossman R, Saibil F, Lariviere L. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997, 112:1069-1077. 10.1016/S0016-5085(97)70117-3, 9097988.
3. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, Ghrayeb J. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993, 30:1443-1453. 10.1016/0161-5890(93)90106-L, 8232330.
4. Olsen T, Cui G, Goll R, Husebekk A, Florholmen J. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol 2009, 44:727-735. 10.1080/00365520902803507, 19294580.
5. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476. 10.1056/NEJMoa050516, 16339095.
6. Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y, Johanns J, Colombel JF, Present D, Sands BE. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012, 18:201-211. 10.1002/ibd.21697, 21484965.
7. Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G, De Hertogh G, Hoffman I, D'Hoore A, Van Steen K, Geboes K, Penninckx F, Rutgeerts P. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008, 2:219-225. 10.1016/j.crohns.2008.03.004, 21172214.
8. Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, Viscido A, Annese V, Riegler G, Meucci G, Marrollo M, Sostegni R, Gasbarrini A, Peralta S, Prantera C. Infliximab in severe ulcerative colitis: short-term results of different infusion regimen and long-term follow-up. Aliment Pharmacol Ther 2007, 26:747-756. 10.1111/j.1365-2036.2007.03415.x, 17697208.
9. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54. 10.1136/gut.2009.183095, 19651627.
10. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, . ACCENT I Study Group Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002, 359:1541-1549. 10.1016/S0140-6736(02)08512-4, 12047962, ACCENT I Study Group.
11. Panaccione R, Ghosh S. Optimal use of biologics in the management of Crohn's disease. Ther Adv Gastroenterol 2010, 3:179-189.
12. Regueiro M, Siemanowski B, Kip KE, Pievy S. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007, 13:1093-1099. 10.1002/ibd.20177, 17480021.
13. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126:1593-1610. 10.1053/j.gastro.2004.02.070, 15168370.
14. Panaccione R, Ghosh S, Middleton S, Marguez JR, Scott BB, Flint L, van Hoogstraten H, Chen AC, Zheng H, Danese S, Rutgeerts P. Combination therapy with infliximab, and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014, 146:392-400. 10.1053/j.gastro.2013.10.052, 24512909.
15. Moran GW, Debeau MF, Kaplan GG, Yang H, Seow CH, Fedorak RN, Dieleman LA, Barkema HW, Ghosh S, Panaccione R, . Alberta Inflammatory Bowel Disease Consortium Phenotypic features of Crohn's disease associated with failure of medical treatment. Clin Gastroenterol Hepatol 2014, 12:434-442. 10.1016/j.cgh.2013.08.026, 23978351, Alberta Inflammatory Bowel Disease Consortium.
16. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, Domenech E, Eliakim R, Eser A, Frater J, Gassull M, Giladi M, Kaser A, Lemann M, Moreels T, Moschen A, Pollok R, Reinisch W, Schunter M, Stange EF, Tilg H, Van Assche G, Viget N, Vucelic B, Walsh A, Weiss G, Yazdanpanah Y, Zabana Y, Travis SP, Colombel JF, . European Crohn's and Colitis Organisation (ECCO) European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91. 10.1016/j.crohns.2009.02.010, 21172250, European Crohn's and Colitis Organisation (ECCO).
17. Oussalah A, Evesque L, Laharie D, Roblin X, Boschetti G, Nancey S, Filippi J, Flourie B, Hebuterne X, Bigard MA, Peyrin-Biroulet L. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010, 105:2617-2625. 10.1038/ajg.2010.345, 20736936.
18. Ferrante M, Arlas MT, Vermelre S, Noman M, Van Assche G, Wolthuis A, De Buck Van Overstraeten A, Ballet V, Gils A, Hoffman I, D'Hoore A, Rutgeerts P. Predictors of long-term relapse-free and colectomy-free survival in patients with ulcerative colitis treated with infliximab [abstract]. ECCO 2013, poster presentation P404.
19. Juliao F, Marquez J, Aristizabal N, Yepes C, Zuleta J, Gisbert JP. Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a Latin American referral population. Digestion 2013, 88:222-228. 10.1159/000355529, 24281150.
20. Cesarini M, Katsanos K, Papamichael K, Ellul P, Lakatos PL, Caprioli F, Kopylov U, Tsianos E, Mantzaris GJ, Ben-Horin S, Danese S, Fiorino G. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis 2014, 46:135-139. 10.1016/j.dld.2013.10.007, 24246151.
21. Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J. A positive response to infliximab in Crohn's disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002, 37:818-824. 10.1080/gas.37.7.818.824, 12190096.
22. Armuzzi A, Peqliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Sociale O, Papa A, De Vitis I, Rapaccini GL, Guidi L. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis 2013, 19:1065-1072. 10.1097/MIB.0b013e3182802909, 23448790.
23. Olsen T, Florholmen J. Clinical, biological, and laboratory parameters as predictors of severity of clinical outcome and response to anti-TNF-alpha treatment in ulcerative colitis. Ulcerative colitis - Treatments, special populations and the future 2011, 61-82. Croatia: InTech, O'Connor M, ISBN: 978-953-307-739-0.
24. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011, 140:1817-1826. 10.1053/j.gastro.2010.11.058, 3749298, 21530748.
25. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003, 98:1309-1314. 10.1111/j.1572-0241.2003.07458.x, 12818275.
26. Matsumura K, Nakase H, Kosugi I, Honzawa Y, Yoshino T, Matsuura M, Kawasaki H, Arai Y, Iwashita T, Nagasawa T, Chiba T. Establishment of a novel mouse model of ulcerative colitis with concomitant cytomegalovirus infection: in vivo identification of cytomegalovirus persistent infected cells. Inflamm Bowel Dis 2013, 19:1951-1963.
27. Yoshino T, Nakase H, Matsuura M, Matsumura K, Honzawa Y, Fukuchi T, Watanabe K, Murano M, Tsujikawa T, Fukunaga K, Matsumoto T, Chiba T. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants. Digestion 2011, 84:3-9. 10.1159/000321911, 21311190.
28. D'Ovidio V, Vernia P, Gentile G, Capobianchi A, Marcheggiano A, Viscido A, Martino P, Caprilli R. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J Clin Virol 2008, 43:180-183. 10.1016/j.jcv.2008.06.002, 18614396.
29. Pillet S, Pozzetto B, Jarlot C, Paul S, Roblin X. Management of cytomegalovirus infection in inflammatory bowel diseases. Dig Liver Dis 2012, 44:541-548. 10.1016/j.dld.2012.03.018, 22538204.
30. Dave M, Loftus EV. Mucosal healing in inflammatory bowel disease - a true paradigm of success?. Gastroenterol Hepatol 2012, 8:29-38.